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THE use of thyroid hormone in metastatic breast cancer was first reported
about 70 years ago by Beatson (1896). He had combined the hormone with
oophorectomy and obtained some good results. Many years later, in 1950
Loeser, a rather forgotten pioneer of modern endocrine therapy used thyroid
hormone combined with androgens to treat metastatic cancer and independently
as a prophylactic measure following radical treatment of breast cancer.
There have also been many reports suggesting the existence ofa causal relation-
ship between the level of thyroid function and cancer, especially of the breast
(Wilkins and Morton, 1963). Edelstyn, Lyons and Welbourn (1958) observed
such an association during routine studies with 1311 performed before hypophy-
sectomy. It was noted that patients in whom the disease was confinied to the
chest wall and local glandular areas had consistently higher indices of thyroid
activity as judged by neck uptake, urinarv excretion and protein bound 1311 levels,
than those patients in whom blood borne spread had taken place. This finding
has since been disputed by Reeve aind his colleagues (1961).
Three years before the above report, in 1955, one of us (A.R.L.) had started a
trial of the value of dessicated thyroid extract as a prophylactic agent following
local mastectomy and radiotherapy in Stage I and II breast cancer. This report
presents the results obtained.
MATERIAL AND METHOD
Only patients with clinical Stage I or Stage II carciniomas of breast treated by
local mastectomy were included in the trial. Post-operative radiation was given
by the Edinburgh technique (McWhirter, 1948).
Two principal groups of patients are presented. One served as the test group
and the other as control.
Selection was based on the year of birth, those with an odd age having thyroid
extract which was replaced for the last two years ofthe trial by thyroxine. Those
with an even age were controls and received nothing. The quantity of hormone
given was adapted to the individual patient. In general three grains of thyroid
extract daily or 0-3 mg. thyroxine was well tolerated.
The weight was recorded at each attendance and estimations of protein bound
iodine (P.B.I.) performed from time to time. Because of a possibility that some
differences in therapeutic effect may exist between the hormones used these
investigations have been analysed separately where numbers permit.THYROID HORMONE TREATMENT IN BREAST CANCER
TABLE I. Number of Patients Included in Series
Breast cancer stage
Number of , -
Groul) patients I II
Control. Nil = 132 75 57
Thyroid = 85 47 38
Thvroxine 38 30) 8
Total in trial 255 152 103
RESULTS
The three groups have been analysed and showni to be similar with respect to
site anid size of neoplasm. A rather higher proportion of Stage I cancers occurred
amongst the patients receiving thyroxine than in either of the other groups. The
probable significance of this is referred to below. There is also a slightly higher
predominance of youiiger women amongst groups receiving either hormone as
compared with the control group. Results obtained are expressed both as disease
free and as the crude total surviving percentage. This latter figure includes all
patients alive at each anniversary with or without recurrent cancer. A miniimum
follow-up of three years is available.
Fig. 1 suggests that patients receiving thyroxine have a rather better chance
of surviving (with or without recurrence) to the 5th anniversary than either of the
other two groups. In Fig. 2 where only recurrence free cases are considered
patients receiving thyroxine again appear to have the better results. These
differences are almost certainly caused by the greater number of Stage I cases in
the thyroxine group. Numbers are too small to allow a comparisoii stage for
stag,e.
Pattern of Tumour Recurrence
In view of our previous observatioins (Edelstyn, Lyons and XVelbourn, 1958)
associating thyroid activity with the type of tumour recurrence, it seemed of
interest to see whether the trial could yield further information on this poilnt.
Wre have therefore examined the pattern of tumour recurrenices observed in the
groups of patients presented. It has been our experience that in general metasta-
sising breast cancer follows one of three patterns each fairly well defined not only
by its clinical presentation but also by its response to endocrine therapy.
(1) Those patients who have widespread secondaries in lungs, liver anid in
brain and who seldom can be helped by endocrine therapy.
(2) Those in whom osseous metastases predominate and in whom a large
percentage benefit from endocrine therapy.
(3) Lastly a group lacking the propensity of blood bornie disseminationi but
growing extensively on the chest wall. The response to therapy is initermediate
between the first two groups.
Because of the small numbers involved all patienits receiving hormoone therapy
have been grouped together.
Table II shows that the proportion of local recurrences is almost twice as high
amongst patients receiving thyroid or thyroxine. The distribution oftheremaining
recurrences shows no difference being divided equallv between the bone and
visceral deposits in both the groups.
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FIG. 2. Patients remaining disease free to 5th anniversary.
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TABLE II.-Sites of Recurrence and Administration of Thyroid
Site Thyroid
of recurrence Control (inc. thyroxine)
Local . 9 (15%) * 12 (26%)
Bone . 25 (43%) . 17 (36%)
Visceral 24 (42%) . 18 (38%o)
WXe have also looked at the time at which recurrences have become clinicallv
detectable in the groups (Table III).
TABLE III.-Time of Recurrence (in months) and Administration of Hormone
Time of
Type of Initial Eventual
recurrence Grou) recurrence death Interval
Local . Control . 28 56- 5 285
Thyroid . 40 58-5 . 18- 6
Bone Control . 22-5 33-4 110
Thyroid . 274 45- 5 18 -1
Visceral . Control 19 5 26-5 . 7-0
Thyroid . 19 0 27 8-0
Table III shows that patients receiving either hormone preparation and subse-
quently developing local recurrences do so at a later stage though eventual death
is not delayed. Those developing bony deposits do so at a similar time in both
groups but the rate of progress is perhaps slower in patients receiving hormones.
In the case of visceral disease no differences of any sort are noted.
No obvious association was found between P.B.I. levels and weight chaniges,
on the one hand and the tvpe of recurrence on the other.
TABLE IV. P.B.I. Levels in the Three Groups
Number of Number of
Groul) patients estimations Mean
Control 61 69 . 5-3
Thvroid . 37 57 . 5-7
Thyroxine 32 51 8-1
A conmparison of P.B.I. values ini the three groups has been made (Table IV).
This w,as done in the hope that it might yield information about the therapeutic
efficiency ofthe hormones used in the trial. With this end in view weight changes
over the period of observation have also been analysed.
No difference between P.B.I. levels in controls and patients on thyroid extract
has been found though it is elevated in those receiving thyroxine. Furthermore,
a study ofweight changes showed that significant gains ofweight (in excess of 10 %
during period of observation) occurred less frequently in the group receiving thv-
roxine as compared with the other groups.
DISCUSSION
Maany workers have investigated the possible existence ofan association between
thyroid function and breast cancer and a number of pathological, epidemiological
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and clinical reports have recently been reviewed by Wilkins and Morton (1963).
Treatment ofmetastatic breast cancer using thyroid hormones has also been tried.
Lemon in 1957 used cortisone and thyroid whilst Gardner, Thomas and Gordon
(1962) more recently used prednisone and triiodothyronine; both ofthese workers
obtaining good results. Emery and Trotter (1963) used triiodothyronine alone,
but found it to be ofno therapeutic value. Wilkins and Morton (1963) using female
mice innoculated with transplantable mammary cancer found that nonle of
four thyroid hormone analogues had any influence on the subsequent development
of the growth.
Our findings indicate that dessicated thyroid extract is valueless as a prophy-
lactic agent after mastectomy. Whilst a first glance at the thyroxine figures might
suggest that the reverse holds good for this substance the predominance of Stage I
cases in the group negates such a conclusion. We cannot therefore agree with
Loeser (1954, 1958) on this point. Alternatively, however, the unsatisfactory
nature of thyroid extract as a therapeutic agent has already been mentioned and
as thyroxine may be more reliable in its effect (Wayne, 1960; McGregor, 1961) a
further examination of its value may be worthwhile in view of the small numbers
here reported. The lower P.B.I. values and the more commonly observed marked
weight gains in the thyroid extract group as compared with the thyroxine group
might substantiate this view. While this may be correctwithrespecttotheweight
gains a comparison of P.B.I. levels probably does not provide relevant information.
Discussing the therapy ofmyxoedema, Lavietes and Epstein (1964) point out that
when a euthyroid state has been obtained the P.B.I. depends on which particular
hormone has been employed. Thus triodothyronine gives levels around zero,
dessicated thyroid values areinthenormal range whilstthose obtained onthyroxinie
are high. Whatever the explanation for these results we shall continue the trial
using thyroxine alone.
Another observation was that in the group receiving either preparation the
pattern of recurrence seemed altered, with a greater proportion of recurrence
being of the local variety. This agrees with the observation of Edelstyn and
colleagues (1958) that a higher level of thyroid function is associated with local
recurrences than with blood borne deposits. They speculated at that timewhether
distant recurrences depressed thyroid function or whether reduced thyroid function
predisposed to distant metastases. Current findings would suggest the latter
explanation is the case and that thyroid function determines in some way the
pattern of metastases.
SUMMARY
A trial of the prophylactic value of thyroid extract and thyroxine administered
routinely after treatment of operable breast cancers has been presented. The
results suggest that these substances are without clinical value.
An interesting incidental observation is that the incidence of local recurrence
is greater amongst the group receiving hormone therapy.
We are very grateful to Sister Mullan ofthe Radiotherapy Out-patient Depart-
ment, Royal Victoria Hospital, Belfast, for taking the many weight estimations
and blood samples. Also to Mr. D. Neill for the P.B.I. estimations. The illus-
trations are by Mr. G. Smith and the typing by Mrs. M. Convey to both of whom
we also express our thanks.
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